DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for spinocerebellar ataxia type 8 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSpinocerebellar ataxia type 8 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for spinocerebellar ataxia type 8 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Spinocerebellar ataxia type 8 is a slowly progressive, dominant ataxia caused by a transcribed but untranslated CTG expansion, not a CAG repeat translated into a polyglutamine tract. It shows dramatic repeat instability and a high degree of reduced penetrance. The broader group of spinocerebellar degenerations has no reliable biomarkers, few animal models, and no universally validated rating scale for clinical trials. As of 2003, only 18 controlled trials for ataxia had been conducted in 25 years, and no FDA-approved drug existed for any SCA.
No abstract in this set reports a trial or any treatment specifically for SCA8. The only drug repurposing data come from a 2024 compassionate-use study of riluzole in six patients with SCA7, a different genetic subtype. In that study, riluzole 50 mg twice daily for a mean of 4.8 years produced no effect on visual function in two patients with advanced retinal damage. Four patients showed initial visual improvement followed by stability up to five years. Two patients had a less steep ataxia deterioration during the first 2.5 years of treatment compared with before treatment. One patient improved on the SARA score soon after starting, then remained stable for 3.5 years before worsening. One visually impaired patient without neurological impairment did not worsen over 3.5 years. Two patients improved soon after therapy and then remained stable for five and three years respectively. No adverse events were recorded. The authors describe a possible beneficial action in SCA7, but the sample is small, uncontrolled, and the disease is not SCA8.
A 2025 review states that autosomal-dominant spinocerebellar ataxias remain incurable, though certain medications and physical therapy may alleviate symptoms. It expresses hope that gene therapy may eventually slow or stop disease progression. A 2023 review on stem cell therapy warns that stem cells are not the answer for all such diseases and that clinics offering stem cell therapy for every incurable disease are proliferating without adequate evidence.
What is still missing for SCA8 specifically: any controlled trial of any drug, any biomarker validated for the subtype, a rating scale proven to capture progression in SCA8, and any preclinical or clinical data on riluzole, gene therapy, or stem cells in SCA8 patients. Funding for natural history studies and stratified trials in this rare, reduced-penetrance disorder remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cytogenetic and Genome Research · 2003 · 39 citations
Molecular genetics of spinocerebellar ataxia type 8 (SCA8)
AbstractWe previously reported that a transcribed but untranslated CTG expansion causes a novel form of ataxia, spinocerebellar ataxia type 8 (SCA8) (Koob et al., 1999). SCA8 was the first example of a dominant spinocerebellar ataxia that is not caused by the expansion of a CAG repeat translated into a polyglutamine tract. This slowly progressive form of ataxia is characterized by dramatic repeat instability and a high degree of reduced penetrance. The clinical and genetic features of the disease are discussed below.
Expert Opinion on Pharmacotherapy · 2003 · 4 citations
Spinocerebellar degeneration
AbstractThe spinocerebellar degenerations/ataxias (SCAs) are a diverse group of rare, slowly progressive, neurological diseases, often inherited but of incompletely understood pathophysiology, which affect the cerebellum and its related pathways. They have few animal models and share no reliable biomarkers. They have, as yet, no universally validated rating scale for use in clinical trials. In the past 25 years, there have been, at most, 18 controlled (Class 1) trials for ataxia, which have focused on neurotransmitter mechanisms. There is currently only one National Institute of Neurological Disorders and Stroke-sponsored drug trial for ataxia (Phase I study of idebenone in Friedreich's ataxia). There are, as yet, no FDA-approved drugs for SCA. Current treatment practices encompass rehabilitation interventions and off-label use of symptomatic medications [1,2].
Long-Term Follow-Up before and during Riluzole Treatment in Six Patients from Two Families with Spinocerebellar Ataxia Type 7
AbstractBACKGROUND: Currently no curative treatment exists for spinocerebellar ataxias (SCAs). Riluzole repurposing was proposed as a symptomatic treatment in different types of cerebellar ataxia. We report a long-term-follow up under riluzole treatment in SCA type 7. METHODS: Six patients received Riluzole 50 mg twice daily on a compassionate use program for a mean of 4.8 years (range 3.5-9). We measured ataxia onset and progression through the Scale for the Assessment and Rating of Ataxia (SARA), and collected extensive ophthalmological data before and after Riluzole treatment. Electrocardiogram and laboratory profile for drug safety were performed every six months. RESULTS: Riluzole treatment showed no effect on visual function in two patients with an advanced retinal damage. Improvements of visual function occurred in four patients followed by ophthalmologic stability up to 5 years after starting treatment. Two patients had a less steep deterioration of ataxia after treatment compared to pre-treatment, during the first 2,5 years of therapy. One showed soon after therapy an improvement of the SARA score, and then overall stability lasting 3,5 years, followed by ataxia worsening. One visually impaired patient without neurological impairment did not worse until the last visit after 3,5 years of follow-up. The remaining 2 patients showed an improvement of SARA scores soon after therapy, and an overall stability lasting respectively 5 and 3 years. No adverse event was registered during the observation period. DISCUSSION: This study suggests a possible beneficial action of Riluzole in SCA7 and provides a detailed description of the ophthalmologic profile of these patients.
Yakut Medical Journal · 2025 · 0 citations · open access
Approaches to the treatment of autosomal-dominant spinocerebellar ataxias
AbstractThe article is devoted to the prospects for the treatment of neurodegenerative diseases with dynamic mutations based on published studies of the search for approaches to the treatment of spinocerebellar ataxia. Although these diseases are incurable, research results show that certain medications and physical therapy can alleviate the symptoms of cerebellar ataxia. Due to the progress made in the study of spinocerebellar ataxia in recent years, there are high hopes that it will be possible to develop gene therapy methods that will slow down the progression of the disease or even stop its development.
Annals of Movement Disorders · 2023 · 0 citations · open access
Stem cell therapy for spinocerebellar ataxias
AbstractStem cells have proved to be the “wonder treatment” for various genetic diseases and holds great potential for the treatment of numerous, but presently incurable maladies. However, stem cells may not be the answer for all such diseases. With the rampant growth of clinics offering stem cell therapy for almost every incurable disease, it is prudent that the indications, ethical considerations, and potential side effects of this treatment are known to the physicians and patients. In this article, we have summarized the available evidence on stem cell therapy in spinocerebellar ataxias.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
